Copyright: ©Author(s) 2026.
World J Hepatol. Mar 27, 2026; 18(3): 114519
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.114519
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.114519
Table 2 Chronic health conditions assessed and incidence of respiratory syncytial virus (n = 49758), n (%)/median (interquartile range)
| n | Age | Female | RSV+ (n) | RSV+ (%) | |
| Cirrhosis | 744 | 53 (63-73) | 229 (30.8) | 2 | 0.3 |
| Ischaemic heart disease | 7316 | 53 (64-75) | 2534 (34.6) | 10 | 0.1 |
| Congestive heart failure | 5551 | 66 (79-87) | 2664 (48.0) | 29 | 0.5 |
| COPD | 3246 | 64 (74-82) | 1551 (47.8) | 24 | 0.7 |
| Chronic kidney disease | 2590 | 71 (81-88) | 1314 (50.7) | 17 | 0.7 |
| Obesity | 1089 | 28 (22-39) | 983 (90.3) | 0 | 0 |
| Diabetes | 33602 | 57 (68-78) | 15536 (46.2) | 63 | 0.2 |
- Citation: Walia N, Lu I, Hannah N, Sood S. Evaluating cirrhosis and respiratory syncytial virus infection: Should we vaccinate? World J Hepatol 2026; 18(3): 114519
- URL: https://www.wjgnet.com/1948-5182/full/v18/i3/114519.htm
- DOI: https://dx.doi.org/10.4254/wjh.v18.i3.114519